stars 1 stars 2 stars 3

Iguana Biotechnology GmbH (Iguana), an innovative BioTech start-up based in Munich, Germany, is pursuing as lead candidate the development of a therapeutic vaccine against Helicobacter pylori, one of the most common infectious diseases worldwide. Currently, about 50% of the world's population is affected by this infection. Early diagnosis and treatment of the infection can significantly reduce the risk of serious gastric diseases such as gastric ulcers, MALT lymphoma and gastric cancer. Due to increasing resistance to conventional antibiotic therapy, the development of effective therapeutic alternatives is essential. Iguana's innovative approach to a therapeutic vaccine meets the urgent need for a therapeutic alternative and to increase the prevention of gastric cancer.

Iguana Biotec Questions

1 people are employed at Iguana Biotec.

Iguana Biotec is based in Munich, Bavaria.

G2 Leader Summer 2026 G2 Best Est ROI Mid-Market Summer 2026 G2 Easiest Admin Mid-Market Summer 2026 G2 Most Implementable Summer 2026 G2 Best Results Mid-Market Summer 2026 G2 Lead Capture Mid-Market Summer 2026 Inc Fastest Growing Private Companies 2026 Inc Best Workplace 2026
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users